CTXRCitius Pharmaceuticals Inc
CTXR
Citius Pharmaceuticals Inc21,615
Mkt Cap
$24.94MVolume
332,171.0052W High
$5.9552W Low
$0.65PE Ratio
-0.25CTXR Fundamentals
Price
$1.26Prev Close
$1.35Open
$1.4150D MA
$1.33Beta
1.19Avg. Volume
588,246.32EPS (Annual)
-$5.97P/B
0.28Rev/Employee
$0.00Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel...
PR Newswire·2d ago
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration PR Newswire CRANFORD, N.J., Nov...
PR Newswire·12d ago
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces the Closing of Registered Direct...
PR Newswire·1mo ago
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million...
PR Newswire·1mo ago
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR...
PR Newswire·2mo ago
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to...
PR Newswire·2mo ago
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and...
PR Newswire·10mo ago
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals and Citius Oncology Announce Unique...
PR Newswire·10mo ago
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced...
PR Newswire·11mo ago
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch...
PR Newswire·11mo ago